IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

"This completed cohort data marks a significant step forward in our efforts to explore the potential of IO102- IO103 as a therapeutic cancer vaccine across a range of solid tumors where there is a high need for new, accessible treatments," said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech. "We look forward to the presentation of this data at the upcoming ESMO Congress and the continued development of our novel immune-modulating cancer vaccine that could potentially improve outcomes for people liv ...